Sun and Taro Generic Drug Antitrust Settlement Awards 200 Million Payout
The Sun and Taro Generic Drug Antitrust Settlement Awards 200 Million Payout settlement offers $200M in total, with individual payouts of $200M to eligible claimants who indirectly purchased, paid for, and/or reimbursed some or all of the purchase price of one or more named generic drugs listed in the settlement agreement (see referenced pages 19–28) between may 1, 2009 and dec. 31, 2019.. The deadline to file is November 9, 2026. Proof of purchase is required.
Deadline: November 9, 2026
Total amount allocated for all claims
Estimated amount per eligible claim
Provide documentation showing you purchased at least one of the named generic drugs during May 1, 2009 to Dec. 31, 2019. Acceptable proof includes receipts or invoices identifying the drug, pharmacy account statements or itemized pharmacy purchase records, and other records showing the drug and amount paid in the class period. Third-party payers may also need to provide additional information such as National Drug Code (NDC) numbers, fill dates, and amounts paid.
Settlement Summary
This lawsuit centers on allegations that two major generic drug manufacturers—Sun Pharmaceutical Industries and Taro Pharmaceuticals—may have coordinated in ways that reduced competition for certain generic medications. According to the notice, consumers and third-party payers who bought, paid for, or reimbursed specified generic drugs between May 1, 2009, and Dec. 31, 2019 may be eligible for cash. The complaint claimed conduct such as price fixing, bid rigging, and market allocation, which—if proven—could have caused “end payers” (like insurers and benefit plans) to pay more than they otherwise would in a competitive market. The settlement is significant because it provides a $200 million fund for affected purchasers, even though Sun and Taro deny wrongdoing and the case is resolved without a final court finding on the merits. The class action was filed to seek compensation for overcharges and to hold companies accountable under federal and state antitrust laws and consumer-protection statutes, plus related common-law theories. Instead of continuing years of litigation, Sun and Taro agreed to settle to avoid further legal costs and uncertainty; the payout is intended to be distributed on a pro rata basis, meaning the amount a claimant receives is proportional to what they spent on covered drugs during the class period. Broader implications include the ongoing scrutiny of generic-drug pricing practices and the role of settlements in deterring collusive behavior, which can be especially important because generic drugs are regulated and heavily relied upon by healthcare systems, including under the Hatch-Waxman framework and pricing/competition rules enforced by bodies like the U.S. Federal Trade Commission and the U.S. Department of Justice—making this dispute part of a larger pattern of antitrust enforcement in pharmaceuticals. For eligible claimants, the practical path to payment involves submitting proof of purchase, meeting geographic and payer-type exclusions, and filing a claim by Nov. 9, 2026, after which the administrator will process claims and distribute the remaining settlement fund, concluding a case that highlights how competition rules can directly affect what patients and payers ultimately pay for generic medicines.
Entities Involved
Related Topics
Eligibility Requirements
- Indirectly purchased, paid for, and/or reimbursed some or all of the purchase price of one or more named generic drugs listed in the settlement agreement (see referenced pages 19–28) between May 1, 2009 and Dec. 31, 2019.
- Purchases occurred in the 50 U.S. states (excluding Indiana and Ohio), the District of Columbia, Puerto Rico, or the U.S. Virgin Islands.
- The claimant did not purchase the drugs for resale and did not purchase directly from any of the defendants.
- Consumers: individuals who bought one or more named generic drugs for personal use via pharmacy or mail-order prescription.
- Third-party payers: entities that paid for and/or reimbursed some or all of the purchase price for members, employees, insureds, participants, or beneficiaries.
- If a class member made both eligible and ineligible purchases, they are included only for the eligible purchases.
Featured Investigations
Important Notice About Filing Claims
Submitting false information in a settlement claim is considered perjury and will result in your claim being rejected. Fraudulent claims harm legitimate class members and may result in legal consequences.
If you are unsure about your eligibility for this settlement, please visit the official settlement administrator’s website using the link provided above. Review the eligibility criteria carefully before submitting a claim.
Class Action Champion is an independent information resource and is not affiliated with any settlement administrator, law firm, or court. We provide settlement information as a service to help connect eligible class members with legitimate settlements.